The Warren Alpert Medical School of Brown University’s Post

After a decade of effort and dedication, the findings of IceCure Medical’s #ICE3 clinical trial on #cryoablation for small, low-risk #breastcancer were presented at the 2024 The American Society of Breast Surgeons conference. ❄️ 96.3% free from local recurrence for patients treated with #ProSense Cryoablation and who received hormone therapy ❄️ 100% doctor and patient satisfaction with the ProSense procedure ❄️ 100% safe procedure – no significant device-related adverse events or complications have been reported For more details, read our new blog post: “A Step Forward Towards Cryoablation for Early-Stage Breast Cancer: Final Five-Year Results of the ICE3 Trial.” for a simple, easy-to-read breakdown of the study: 🔗 https://lnkd.in/dnCcDP_x

Trends in management and related outcomes for occult primary breast cancer Purpose: Occult Primary Breast Cancer (OPBC) is a rare clinical condition in which breast cancer is located within the axillary lymph nodes, but no primary tumor is identified in the breast. We evaluated trends of neoadjuvant chemotherapy (NAC) use and subsequent axillary procedures in OPBC as well as outcomes for these patients. Methods: The National Cancer Database was used to identify adult women with cT0N1-3M0 breast cancer between 2012 to 2021 that underwent axillary lymph node surgery. Kaplan-Meier curves were used to evaluate survival between groups. Results: 2759 patients met inclusion criteria. 86.2% underwent ALND alone in 2012, and this decreased to 65.6% in 2021. 4.7% underwent SLNB alone in 2012 and this increased to 16.2% in 2021 (p < 0.001). For patients who had undergone NAC, 46.4% of ALND patients had nodal pathologic complete response (nPCR), compared to 42.7% of SLNB + ALND and 66.4% of SLNB only patients. For patients with nPCR, there was no difference in overall survival (OS) between ALND, SLNB + ALND, and SLNB alone groups (p = 0.9912). Conclusion: Most OPBC patients were treated with ALND, with a modest increase towards SLNB use during the study period. There was no difference in OS with respect to axillary surgical procedure in our population for those with nPCR after NAC. This suggests that for carefully selected OPBC patients with an excellent clinical response to NAC and negative SLNB, omission of ALND may be considered. https://lnkd.in/d5dUTE7u

More practice-changing results from the KEYNOTE-522 trial. 🎉 Such great news for patients with triple negative breast cancer (TNBC), the most aggressive subtype of breast cancer. There’s very few treatment options for TBNC, so having one that provides improved outcomes with fewer side effects than chemotherapy is significant. Most remarkable, patients who still had residual tumor at surgery following neoadjuvant treatment received the most benefit in terms of overall survival. #BreastCancer #TNBC #TripleNegativeBreastCancer #Keytruda #ClinicalTrials #ClinicalResearch https://lnkd.in/g58Q3JqW

🌟 Groundbreaking Advance in Endometrial Cancer Treatment: DUO-E Trial Unveils Promising Results! (Published Jan 20, 2024) 🌟 🔬 The field of oncology is witnessing a monumental shift with the recent findings from the phase III DUO-E trial. This study marks a significant step forward in treating advanced or recurrent endometrial cancer, a challenging field that has long relied on traditional methods like surgery, radiation, and chemotherapy. 🎯 The trial highlights the efficacy of combining durvalumab (an immune checkpoint inhibitor) with carboplatin/paclitaxel chemotherapy, and in some cases, adding olaparib (a PARP inhibitor). What makes this groundbreaking? The impressive hazard ratios for progression-free survival (PFS) - 0.71 for durvalumab and an even more remarkable 0.55 for durvalumab + olaparib. 💡 Compared to foundational studies in gynecologic malignancies, such as the GOG-0218 and ICON7 trials in ovarian cancer, the DUO-E trial demonstrates a more substantial improvement in PFS. It not only surpasses previous benchmarks but also shows promise across various genetic profiles of endometrial cancer, indicating its potential as a universal treatment approach. 🌐 This development could revolutionize the way we approach endometrial cancer, shifting from traditional methods to a more personalized, targeted, and multimodal strategy. The integration of immunotherapy and targeted agents from the outset is poised to redefine clinical guidelines. 👉 Are you intrigued by these trailblazing results and want to delve deeper into their clinical significance? Click the link to read our full assessment and understand how the DUO-E trial could reshape the landscape of endometrial cancer treatment. 🔗 https://lnkd.in/dSVnsrRZ #CancerResearch #EndometrialCancer #OncologyInnovation #DUOETrial #Durvalumab #Olaparib #MedicalAdvances2024 #HealthcareTransformation

#Immunotherapy Immunotherapy before Surgery Significantly Increases Cancer-Free Outcomes in Bowel Cancer Patients Researchers at University College London (UCL) and University College London Hospitals (UCLH) have discovered that an immunotherapy drug, pembrolizumab, significantly increases the number of patients who are cancer-free after surgery for bowel cancer, according to interim results from the NEOPRISM-CRC phase II clinical trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The study investigated whether pembrolizumab could improve outcomes for patients with stage two or stage three MMR deficient/MSI-High bowel cancer. This genetic profile, present in 10–15 percent of stage two or three bowel cancer patients, represents about 2,000–3,000 cases annually in the U.K. The trial included 32 patients from five U.K. hospitals who were treated with pembrolizumab for nine weeks before surgery instead of the usual combination of surgery and chemotherapy

Majority of patients with pancreatic cancer in the Netherlands do not receive chemotherapy or other tumor-targeted treatment In a concerted effort to improve pancreatic cancer care in the Netherlands, a nationwide randomized trial involving over 5800 patients assessed patient outcomes before and after the implementation of guidelines based on the latest best practices. One of the key findings of this study is that over 60% of patients with pancreatic cancer did not receive any tumor-targeted therapy, a fact that is reflected in the poor 1-year survival rate (24%) which did not improve measurably. The study, published in JAMA Surgery, offers insights into the real-world challenges of treating pancreatic cancer and calls for identifying strategies that can make a meaningful difference in the lives of these patients. Read more on our website: https://lnkd.in/eP-YEtYC Amsterdam UMC - Cancer Center Amsterdam, #CancerResearch #CancerCare #PancreaticCancer

📃Scientific paper: The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan Abstract: Anaplastic thyroid cancer (ATC) is a rare but lethal thyroid cancer. Dabrafenib and trametinib has been the standard treatment for the patients with BRAF mutation based on phase II study. This study aimed to exam the impact of dabrafenib and trametinib in ATC patients. ATC patients treated in three institutes in Taiwan were retrospectively reviewed. The clinical features, BRAF status, and survivals were collected. Multivariate analysis was performed to determine the independent prognostic factors. A total of 44 ATC patients were enrolled in current study. Twelve (50%) out of 24 detected patients had BRAF V600E mutation and eleven received dabrafenib and trametinib treatment. Patients treated with dabrafenib and trametinib had longer overall survival (OS) than the patients without treatment with dabrafenib and trametinib (median OS: 10.4 months vs. 3.3 months, P=0.05). The objective response rate was 81.8% and progress-free survival was 7.4 months. Multivariate analysis identified prior surgery, treatment with dabrafenib and trametinib and metastasis to lung, brain, and bone were significant prognostic factors for OS. The benefit of prior surgery was significant in patients receiving dabrafenib and trametinib (P=0.017) rather than those without dabrafenib and trametinib (P=0.067). The current study provides the real-world evidence that targeted therapy with dabrafenib and trametinib was effective and significantly improved the OS for ATC patients. The role of pr... Continued on ES/IODE ➡️ https://etcse.fr/mMt ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan Abstract: Anaplastic thyroid cancer (ATC) is a rare but lethal thyroid cancer. Dabrafenib and trametinib has been the standard treatment for the patients with BRAF mutation based on phase II study. This study aimed to exam the impact of dabrafenib and trametinib in ATC patients. ATC patients treated in three institutes in Taiwan were retrospectively reviewed. The clinical features, BRAF status, and survivals were collected. Multivariate analysis was performed to determine the independent prognostic factors. A total of 44 ATC patients were enrolled in current study. Twelve (50%) out of 24 detected patients had BRAF V600E mutation and eleven received dabrafenib and trametinib treatment. Patients treated with dabrafenib and trametinib had longer overall survival (OS) than the patients without treatment with dabrafenib and trametinib (median OS: 10.4 months vs. 3.3 months, P=0.05). The objective response rate was 81.8% and progress-free survival was 7.4 months. Multivariate analysis identified prior surgery, treatment with dabrafenib and trametinib and metastasis to lung, brain, and bone were significant prognostic factors for OS. The benefit of prior surgery was significant in patients receiving dabrafenib and trametinib (P=0.017) rather than those without dabrafenib and trametinib (P=0.067). The current study provides the real-world evidence that targeted therapy with dabrafenib and trametinib was effective and significantly improved the OS for ATC patients. The role of pr... Continued on ES/IODE ➡️ https://etcse.fr/mMt ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

**Oral Cancer Topic No. 4:Unveiling Spindle Cell Carcinoma: Insights into Diagnosis, Treatment, and Awareness 1. **Identification**: Spindle cell carcinoma (SCC) is a rare type of cancer characterized by elongated spindle-shaped cells, often found in the skin, lungs, or digestive tract. 2. **Diagnostic Challenge**: Diagnosing SCC can be challenging due to its resemblance to other types of cancer, emphasizing the need for accurate pathological assessment. 3. **Treatment Options**: Treatment modalities for SCC vary based on factors such as tumor location, size, and stage. Options may include surgery, radiation therapy, and chemotherapy. 4. **Importance of Early Detection**: Early detection of spindle cell carcinoma is crucial for timely intervention and improved outcomes. Increased awareness among healthcare professionals can lead to earlier diagnoses. 5. **Multidisciplinary Approach**: Managing SCC often requires a multidisciplinary team involving oncologists, pathologists, surgeons, and other specialists to tailor treatment plans to individual patient needs. 6. **Patient Education and Support**: Educating patients about spindle cell carcinoma, its symptoms, and available treatment options empowers them to participate actively in their care and decision-making process. 7. **Research and Innovation**: Ongoing research and innovation in cancer treatment are essential for advancing our understanding of spindle cell carcinoma and developing more effective therapies. 8. **Advocacy and Awareness**: By raising awareness about spindle cell carcinoma within the medical community and beyond, we can improve early detection, support research efforts, and ultimately enhance patient outcomes. Let's work together to increase awareness and understanding of spindle cell carcinoma, ultimately making a positive impact on cancer care. #SpindleCellCarcinoma #CancerAwareness #MedicalResearch